Nusinersen Injection Application Scope

Nusinersen is used for the treatment of spinal muscular atrophy (SMA), a genetic disorder characterized by progressive muscle weakness and atrophy caused by mutations in the SMN1 gene. It is effective in patients with Types 1, 2, and 3 SMA, improving motor function and slowing disease progression.

Nusinersen Injection Characteristics

Ingredients: Antisense oligonucleotide targeting SMN2 gene splicing to increase functional SMN protein levels.
Properties: A clear and colourless to slightly yellow sterile solution for intrathecal injection.
Dosage Form: Intrathecal injection.
Specification: 12 mg/5 mL per vial.
Packaging Specification: Single-use glass vials in individual packaging.
Storage: Store at 2°C–8°C (36°F–46°F). Do not freeze. Protect from light.
Expiry Date: Typically 24 months from the date of manufacture under proper storage conditions.
Executive Standard: As per regulatory authority guidelines (e.g., FDA, EMA).
Approval Number: YHZ2300353
Date of Revision: To be updated per version.
Manufacturer: Biogen.

Guidelines For The Use Of Nusinersen Injection

Dosage and Administration:
- Initial treatment: Four loading doses (12 mg each) administered intrathecally on Days 0, 14, 28, and 63.
- Maintenance dose: 12 mg every 4 months thereafter.
- Administration: Intrathecal injection by a healthcare professional experienced in lumbar puncture.
Adverse Reactions:
- Common: Headache, nausea, vomiting, and back pain following lumbar puncture.
- Rare: Increased risk of infections, respiratory issues, or kidney toxicity.

Nusinersen Injection Limitations

Contraindications:
- Hypersensitivity to Nusinersen or any of its excipients.
Precautions:
- Monitor for post-lumbar puncture complications (e.g., headaches, meningitis).
- Regularly assess renal function and platelet counts during treatment.
- Use with caution in patients with concurrent infections or bleeding disorders.

Nusinersen Injection Interactions

No significant drug-drug interactions have been identified.
Avoid combining with experimental drugs for SMA without medical consultation.

Note: If there is new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYueMed. It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.